Shionogi, BioVersys team up on ansamycin antibiotics in deal worth up to $614M

BioVersys is entering a pact with Shionogi to advance the Swiss biotech’s antibiotic program targeting non-tuberculous mycobacteria, with over half a billion dollars in biobucks on the line. Shionogi is spending CHF 5 million ...